ROSEMARY BUFALO: Open Payments
NPI 1770281230 · FRAMINGHAM, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$318 in 15 payments from 10 companies in 2025. Trend: 2023 $384 · 2024 $1,761 · 2025 $318
Food & beverage: $318
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 3 | $69 |
| Amgen Inc. | 3 | $66 |
| Novo Nordisk Inc | 2 | $40 |
| Ardelyx, Inc. | 1 | $25 |
| AstraZeneca Pharmaceuticals LP | 1 | $23 |
| Merck Sharp & Dohme LLC | 1 | $23 |
| Novartis Pharmaceuticals Corporation | 1 | $22 |
| Exact Sciences Corporation | 1 | $21 |
| Lilly USA, LLC | 1 | $16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
Products named: FANAPT, Repatha, JARDIANCE, IBSRELA, FARXIGA, GARDASIL 9, ENTRESTO, The Cologuard Plus Collection Kit.
Industry payments across MA — which companies pay providers there.
